Synthesis, modeling, and in vitro activity of (3′S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3′-sugar alcohol on trkA tyrosine kinase activity

Journal of Medicinal Chemistry

Volumn 48, Issue 11, 2005, Pages 3776-3783

  Gingrich, Diane E ^a   Yang, Shi X ^a   Gessner, George W ^a   Angeles, Thelma S ^a   Hudkins, Robert L ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUTAMIC ACID; K 252A; PROTEIN TYROSINE KINASE A; SUGAR ALCOHOL;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DIASTEREOISOMER; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; EPIMER; GEOMETRY; HYDROGEN BOND; IC 50; IN VITRO STUDY; ISOMER; MOLECULAR MODEL; MOUSE; NONHUMAN; STEREOCHEMISTRY;

ANIMALS; CARBAZOLES; HYDROGEN BONDING; HYDROPHOBICITY; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN KINASE C; RECEPTOR, TRKA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUGAR ALCOHOLS; THERMODYNAMICS;

EID: 20144381281     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040178m     Document Type: Article

References (52)

1. (a) Glass, D. J.; Yancopoulos, G. D. The neurotrophins and their receptors. Trends Cell Biol. 1993, 3, 262-268.
2. (b) Meakin, S. O.; Shooter, E. M. The nerve growth factor family of receptors. Trends Neurosci. 1992, 15, 323-331.
3. (c) Lee, F. S.; Kim, A. H.; Khursigara, G.; Chao, M. V. The uniqueness of being a neurotrophin receptor. Curr. Opin. Neurobiol. 1994, 25, 1349-1361.
4. (d) Ross, A. H. Identification of tyrosine kinase Trk as a nerve growth factor receptor. Cell Regul. 1991, 2, 685-690.
5. (e) Ullrich, A.; Schlessinger, J. Signal transduction by receptor with tyrosine kinase activity. Cell 1990, 61, 203-212.
6. (f) Kaplan, D. R.; Hempstead, B. L.; Martin-Zanca, D.; Chao, M. V.; Parada, L. F. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 1991, 252, 554-558.
7. Kaplan, D. R.; Stephens, M. R. Neurotrophin signal transduction by the Trk receptor. J. Neurobiol. 1994, 25, 1404-1417.
8. (a) Thoenen, H.; Barde, Y. A. Physiology of nerve growth factor. Physiol. Rev. 1980, 60, 1284-1335.
9. (b) DiStefano, P. S. Pharmacology of neurotrophic factors in models of neurodegenerative diseases. Annu. Rep. Med. Chem. 1993, 28, 11-17.
10. (c) Lad, S. P.; Neet, K. E.; Mufson, E. J. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Current Drug Targets- CNS and Neurological Disorders 2003, 2, 315-334.
11. (a) Ruggeri, B. A.; Miknyoczki, S. J.; Singh, J.; Hudkins, R. L. Role of Neurotrophin-Trk interactions in oncology: the antitumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models. Curr. Med. Chem. 1999, 6, 845-857.
12. (b) Miknyoczki, S. J.; Klein-Szanto, A. J. P.; Ruggeri, B. A. Neurotrophin-trk receptor interactions in neoplasia: a possible role in interstitial and perineural invasion in ductal pancreatic cancer. Crit. Rev. Oncog. 1996, 7, 89-100.
13. (c) Miknyoczki, S. J.; Lang, L.; Klein-Szanto, A. J. P.; Dionne, C. A.; Ruggeri, B. A. Neurotrophins and trk receptors in human pancreatic ductal adrenocarcinoma: Expression patterns and effects on in vitro invasive behavior. Int. J. Cancer 1999, 81, 417-427.
14. (d) Miknyoczki, S. J.; Wan, W.; Chang, H.; Dobrzanski, P.; Ruggeri, B. A.; Dionne, C. A.; Buchkovich, K. The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenographs in nude mice. Clin. Cancer Res. 2002, 8, 1924-1931.
15. (e) Pflug, B. R.; Dionne, C.; Kaplan, D. R.; Lynch, J.; Djakiew, D. Expression of a high affinity nerve growth factor receptor in the human prostate. Endocrinology 1995, 136, 262-268.
16. Tagliabue, E.; Castiglioni, F.; Ghirelli, C.; Modugno, M.; Asnaghi, L.; Somenzi, G.; Melini, C.; Menard, S. Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J. Biol. Chem. 2000, 275, 5388-5394.
17. (a) Djakiew, D.; Delsite, R.; Pflug, B.; Wrathall, J.; Lynch, J. H.; Onoda, M. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res. 1991, 51, 3304.
18. (b) Weeraratna, A. T.; Dalrymple, S. L.; Lamb, J. C.; Denmeade, S. R.; Miknyoczki, S.; Dionne, C. A.; Isaacs, J. T. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models due to its selective induction of apoptosis of prostate cancer cell. Clin. Cancer Res. 2001, 7, 2237-2245.
19. (c) Weeraratna, A. T.; Arnold, J. T.; George, D. J.; DeMarzo, A.; Isaacs, J. T. Rational basis for trk inhibition therapy for prostate cancer. Prostate 2000, 45, 140-148.
20. (d) Weeraratna, A. T.; Dalrymple, S. L.; Lamb, J. C.; Denmeade, S. R.; Miknyoczki, S.; Dionne, C. A.; Isaacs, J. T. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models due to its selective induction of apoptosis of prostate cancer cell. Clin. Cancer Res. 2001, 7, 2237-2245.
21. (a) Sezaki, M.; Sasaki, T.; Nakazawa, T.; Takeda, U.; Iwata, M.; Watanabe, T.; Koyama, M.; Kai, F.; Shomura, T.; Kojima, M. A new antibiotic SF-2370 produced by Actinomadura. J. Antibiot. 1985, 38, 1437-1439.
22. (b) Kase, H.; Iwahashi, K; Matsuda, Y. K-252a, a potent inhibitor of protein kinase C from microbial origin. J. Antibiot. 1986, 39, 1059-1065.
23. (c) Yasuzawa, T.; Iida, T.; Yoshida, M.; Hirayama, N.; Takahashi, M.; Shirahata, K.; Sano, H. The structures of novel protein kinase c inhibitors K252a, b, c, and d. J. Antibiot. 1986, 39, 1072-1078.
24. Angeles, T. S.; Yang, S. X.; Steffler, C.; Dionne, C. A.; Kinetics of trkA tyrosine kinase activity and inhibition by K-252a. Arch. Biochem. Biophys. 1998, 349, 267-274.
25. Angeles, T. S.; Steffler, C.; Bartlett, B. A.; Hudkins, R. L.; Stephens, R. M.; Kaplan, D. R.; Dionne, C. A. Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity. Anal. Biochem. 1996, 206, 49-55.
26. (a) Berg, M. M.; Sternberg, D. W.; Parada, L. F.; Chao, M. V. K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity. J. Biol. Chem. 1992, 267, 13-16.
27. (b) Tarpley, P. Lamballe, F., Barbacid, M. K-252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene 1992, 7, 371-381.
28. (c) Ohmichi, M.; Decker, S. J.; Pang, I.; Saltiel, A. R. Inhibition of the cellular actions of nerve growth factor by staurosporine and K-252a results from the attenuation of the activity of the trk tyrosine kinase. Biochemistry 1992, 31, 4034-4039.
29. (d) Muroya, K; Hashimoto, Y.; Hattori, S.; Nakamuru, S. Specific inhibition of NGF receptor tyrosine kinase activity by K-252a. Biochim. Biophys. Acta 1992, 1135, 353-356.
30. (e) Nye, S. H.; Squinto, S. P.; Glass, D. J.; Stitt, T. N.; Hantzopoulos, P.; Macchi, M. J.; Lindsaay, N. S.; Ip, N. Y.; Yancopoulos, G. D. K-252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses. Mol. Biol. Cell 1992, 3, 677-683.
31. Knusel, B.; Hefti, H. K-252 compounds: modulators of neurotrophin signal transduction. J. Neurochem. 1992, 59, 1987-1995.
32. (a) Hudkins, R. L.; Iqbal, M.; Park, C.-H.; Goldstein, J.; Herman, J. L.; Shek, E.; Murakata, C.; Mallamo, J. P. Prodrug esters of the indolocarbazole CEP-751. Bioorg. Med. Chem. Lett. 1998, 8, 1873-1876.
33. (b) Dionne, C.; Camoratto, A.; Jani, J.; Emerson, E.; Neff, N.; Vaught, J.; Murakata, C.; Djakiew, D.; Lamb, J.; Bova, S.; George, D.; Isaacs, J. Cell cycle independent-death of prostate adenocarcinoma is induced by trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin. Cancer Res. 1998, 4, 1887-1898.
34. (c) Camoratto, A. M.; Jani, J. P.; Angeles, T. S.; Maroney, A. C.; Sanders, C. Y.; Murakata, C.; Neff, N. T.; Vaught, J. L.; Isaacs, J. T.; Dionne, C. A. CEP-751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. Int. J. Cancer 1997, 72, 673-679.
35. Miknyoczki, S. J.; Chang, H.; Klein-Szanto, A.; Dionne, C. A.; Ruggeri, B. A. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin. Cancer Res. 1945, 5, 2205-2212.
36. George, D. J.; Dionne, C. A.; Jani, J.; Angeles, T.; Murakata, D.; Lamb, J.; Isaacs, J. T. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. 1999, 59, 2395-2401.
37. (a) Kaneko, M.; Saito, Y.; Saito, H.; Matsumoto, T.; Matsuda, Y.; Vaught, J. L.; Dionne, C. A.; Angeles, T. S.; Glicksman, M. A.; Neff, N. T.; Rotella, D. P.; Kauer, J. C.; Mallamo, J. P.; Hudkins, R. L.; Murakata, C. Neurotrophic 3,9-bis[(alkylthiomethyl]- and -[bis(alkoxymethyl)]-K-252a derivatives. J. Med. Chem. 1997, 40, 1863-1869.
38. (b) Murakata, C.; Kaneko, M.; Gessner, G.; Angeles, T. S.; Ator, M. A.; O'Kane, T. M.; McKenna, B. A. W.; Thomas, B. A.; Mathiasen, J. R.; Saporito, M. S.; Bozyczko-Coyne, D.; Hudkins, R. L. Mixed lineage kinase activity of indolocarbazole analogs. Bioorg. Med. Chem. Lett. 2002, 12, 147-150.
39. (c) Dionne, C. A.; Contreras, P. C.; Murakata, C. Use of indolocarbazole derivatives to treat a pathological condition of the prostate. US 5516771.
40. Gingrich, D. E.; Hudkins, R. L. Synthesis and kinase inhibitory activity of 3′-(S)-epi-K-252a. Bioorg. Med. Chem. Lett. 2002, 12, 2829-2831.
41. (a) Hudkins, R. L.; Gingrich, D. 3′-Epimeric K-252 derivatives. US 6093713.
42. (b) Hudkins, R. L.; Gingrich, D. 3′-Epimeric K-252 derivatives for treating neurological disorders and cancer. US 6451786.
43. Murakata, C.; Sato, A.; Takahashi, M.; Kobayashi, E.; Morimoto, M.; Akinaga, S.; Hirata, T.; Mochida, K.; Kase, H.; Yamada, K.; Iwashashi, K. US 4923986.
44. Corey, E. J.; Winter, R. A. E. A new stereospecific olefin synthesis from 1,3-diols. J. Am. Chem. Soc. 1963, 85, 2677-2680.
45. Goekjian, P. G.; Jirousek, M. R. Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr. Med. Chem. 1999, 6, 877-903.
46. NTR. J. Neurochem. 1997, 68, 88-94.
47. (b) Maroney, A. C.; Lipfert, L.; Forbes, M. E.; Glicksman, M. A.; Neff, N. T.; Siman, R.; Dionne, C. A. K-252a induces tyrosine phosphorylation of the focal adhesion kinase and neurite outgrowth in human neuroblastoma SH-SY5Y cells. J. Neurochem. 1995, 64, 540-549.
48. Schierling, N.; Knapp, S.; Marconi, M.; Flocco, M. M.; Cui, J.; Pergeo, R.; Rusconi, L.; Cristiani, C. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met and its complex with the microbial alkaloid K-252a. PNAS, 2003, 100, 12654-12659.
49. Mohammadi, M.; McMahon, G.; Sun, L. Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276, 955-960.
50. Pitt, A. M.; Lee, C. High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate. J. Biomol. Screening 1996, 1, 47-51.
51. Rotin, D.; Margolis, B.; Mohammadi, M.; Daly, R. J.; Daum, G.; Li, N.; Fischer, E. H.; Burgess, W. H.; Ullrich, A.; Schlessinger, J. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. EMBO J. 1992, 11, 559-567.
52. Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Meyer, S.; Robinson, C.; Ruggeri, B. A.;. Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent VEGF receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)-indeno[2,1-a] pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46, 5375-5388.